GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » Operating Margin %

Pharmaresearch Bio Co (XKRX:217950) Operating Margin % : 31.07% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Pharmaresearch Bio Co Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Pharmaresearch Bio Co's Operating Income for the six months ended in Dec. 2023 was ₩6,223 Mil. Pharmaresearch Bio Co's Revenue for the six months ended in Dec. 2023 was ₩20,031 Mil. Therefore, Pharmaresearch Bio Co's Operating Margin % for the quarter that ended in Dec. 2023 was 31.07%.

The historical rank and industry rank for Pharmaresearch Bio Co's Operating Margin % or its related term are showing as below:

XKRX:217950' s Operating Margin % Range Over the Past 10 Years
Min: -12.08   Med: 20.06   Max: 31.07
Current: 31.07


XKRX:217950's Operating Margin % is ranked better than
94.74% of 1026 companies
in the Biotechnology industry
Industry Median: -158.97 vs XKRX:217950: 31.07

Pharmaresearch Bio Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Pharmaresearch Bio Co's Operating Income for the six months ended in Dec. 2023 was ₩6,223 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was ₩6,223 Mil.


Pharmaresearch Bio Co Operating Margin % Historical Data

The historical data trend for Pharmaresearch Bio Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaresearch Bio Co Operating Margin % Chart

Pharmaresearch Bio Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial -12.08 6.15 24.81 20.06 31.07

Pharmaresearch Bio Co Semi-Annual Data
Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin % Get a 7-Day Free Trial -12.08 6.15 24.81 20.06 31.07

Competitive Comparison of Pharmaresearch Bio Co's Operating Margin %

For the Biotechnology subindustry, Pharmaresearch Bio Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaresearch Bio Co's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaresearch Bio Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Pharmaresearch Bio Co's Operating Margin % falls into.



Pharmaresearch Bio Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Pharmaresearch Bio Co's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=6223.276 / 20030.641
=31.07 %

Pharmaresearch Bio Co's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=6223.276 / 20030.641
=31.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaresearch Bio Co  (XKRX:217950) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Pharmaresearch Bio Co Operating Margin % Related Terms

Thank you for viewing the detailed overview of Pharmaresearch Bio Co's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaresearch Bio Co (XKRX:217950) Business Description

Traded in Other Exchanges
N/A
Address
641-3, Saimdang-ro, Gangwon-do, Gangneung-si, KOR, 13494
Pharmaresearch Bio Co Ltd is a Korea-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, sale, and marketing of biopharmaceutical products. Its product is ReNTox Injections, and Clostridium Botulinum Toxin type A is in pipeline.

Pharmaresearch Bio Co (XKRX:217950) Headlines

No Headlines